Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here?

Moderna (MRNA) stock closed higher on Wednesday after the FDA reversed its earlier refusal-to-file decision on the company’s mRNA-1010 seasonal influenza vaccine. 

As the regulatory agency agreed to review MRNA’s revised application, its stock price rallied past its 20-day moving average (MA), signaling bullish momentum could sustain in the near term.

Fundamentals

See More
  • Market Capitalization, $K 18,208,204
  • Shares Outstanding, K 390,734
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,074 M
  • EBITDA $ -2,926 M
  • 60-Month Beta 1.32
  • Price/Sales 8.83
  • Price/Cash Flow N/A
  • Price/Book 1.98

Options Overview Details

View History
  • Implied Volatility 75.46% (-1.74%)
  • Historical Volatility 83.58%
  • IV Percentile 66%
  • IV Rank 42.42%
  • IV High 104.55% on 04/08/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 7) 3.65 (7.34%)
  • Put/Call Vol Ratio 0.18
  • Today's Volume 123,554
  • Volume Avg (30-Day) 92,796
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 1,010,811
  • Open Int (30-Day) 957,643
  • Expected Range 46.05 to 53.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -2.04
  • Number of Estimates 8
  • High Estimate -1.65
  • Low Estimate -2.43
  • Prior Year -2.52
  • Growth Rate Est. (year over year) +19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.65 +35.59%
on 02/11/26
55.20 -9.96%
on 01/22/26
+7.87 (+18.81%)
since 01/16/26
3-Month
22.28 +123.07%
on 11/21/25
55.20 -9.96%
on 01/22/26
+25.52 (+105.54%)
since 11/19/25
52-Week
22.28 +123.07%
on 11/21/25
55.20 -9.96%
on 01/22/26
+13.80 (+38.44%)
since 02/19/25

Most Recent Stories

More News
US stocks slip as AI fears keep rumbling and oil prices climb

U.S. stocks fell, while oil prices climbed

APO : 118.34 (-5.21%)
META : 644.78 (+0.24%)
NVDA : 187.90 (-0.04%)
ARES : 129.85 (-3.08%)
OWL : 11.58 (-5.93%)
$SPX : 6,861.89 (-0.28%)
$IUXX : 24,797.34 (-0.41%)
ETSY : 48.14 (+9.28%)
EBAY : 84.75 (+3.13%)
CVNA : 332.79 (-7.95%)
$DOWI : 49,395.16 (-0.54%)
MRNA : 49.70 (+6.65%)
Moderna to Present at Upcoming Conferences in March 2026

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:

MRNA : 49.70 (+6.65%)
FDA will drop two-study requirement for new drug approvals, aiming to speed access

The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals

$SPX : 6,861.89 (-0.28%)
$DOWI : 49,395.16 (-0.54%)
MRNA : 49.70 (+6.65%)
$IUXX : 24,797.34 (-0.41%)
Nvidia leads the US stock market higher

The U.S. stock market ticked higher, led by its most influential stock, Nvidia

NFLX : 77.00 (-1.27%)
NVDA : 187.90 (-0.04%)
META : 644.78 (+0.24%)
BAC : 52.77 (-1.11%)
$SPX : 6,861.89 (-0.28%)
ADI : 345.30 (-0.31%)
$IUXX : 24,797.34 (-0.41%)
GIS : 44.80 (-1.23%)
PSKY : 10.94 (-1.62%)
CDNS : 296.59 (-2.76%)
$DOWI : 49,395.16 (-0.54%)
MRNA : 49.70 (+6.65%)
Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here?

Moderna shares extend gains as FDA reverses its refusal-to-file decision on the firm’s influenza vaccine. Here’s why MRNA shares still aren’t attractive to own in 2026.

MRNA : 49.70 (+6.65%)
Moderna says the FDA will consider its new flu shot after resolving a public dispute

Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults after all

$SPX : 6,861.89 (-0.28%)
$DOWI : 49,395.16 (-0.54%)
MRNA : 49.70 (+6.65%)
$IUXX : 24,797.34 (-0.41%)
Why Moderna (MRNA) Stock Is Trading Up Today

Why Moderna (MRNA) Stock Is Trading Up Today

MRNA : 49.70 (+6.65%)
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review

MRNA : 49.70 (+6.65%)
3 Stocks Under $50 with Warning Signs

3 Stocks Under $50 with Warning Signs

MTCH : 30.69 (+1.35%)
GTES : 27.77 (+2.36%)
MRNA : 49.70 (+6.65%)
Stocks Recover on Strength in Apple and Airline Stocks

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.10%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.13%. March E-mini...

ALK : 52.13 (-6.64%)
UAL : 110.05 (-5.88%)
B : 48.55 (+0.68%)
AAPL : 260.58 (-1.43%)
INTU : 381.54 (-2.06%)
HL : 22.79 (+3.50%)
CDE : 24.06 (+6.51%)
FISV : 61.53 (-2.35%)
DDOG : 120.60 (-0.97%)
MASI : 175.33 (-0.16%)
$IUXX : 24,797.34 (-0.41%)
DHR : 211.25 (+1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 56.17
2nd Resistance Point 53.31
1st Resistance Point 51.51
Last Price 49.70
1st Support Level 46.85
2nd Support Level 43.99
3rd Support Level 42.19

See More

52-Week High 55.20
Last Price 49.70
Fibonacci 61.8% 42.62
Fibonacci 50% 38.74
Fibonacci 38.2% 34.86
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar